While a higher GBP5 level was probably correlated with no complete response in breast cancer patients received doxorubicin neoadjuvant therapy, GBP5 upregulation appeared to significantly (p = 0.031) predict pathologic complete response in breast cancer patients receiving docetaxel neoadjuvant therapy (Figure 4A). This evidence concerns the gene GBP5 and breast cancer.